The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | TLS in patients with CLL treated with venetoclax
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a retrospective study investigating rates of tumor lysis syndrome (TLS) and outcomes for patients with chronic lymphocytic leukemia (CLL) treated with venetoclax in clinical trial and post-marketing settings. The potent pro-apoptotic effect of venetoclax on CLL cells means that venetoclax treatment poses a risk of inducing TLS. With current mitigation measures, the incidence of TLS was 1.8%, indicating that mitigation measures successfully mitigated TLS for patients being treated with venetoclax. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
